AVITA Medical Inc logo

AVITA Medical Inc - ADR

ASX:AVH (USA)   ADR
A$ 2.80 (-5.08%) Apr 19
At Loss
P/B:
4.64
Market Cap:
A$ 359.88M ($ 230.71M)
Enterprise V:
A$ 287.61M ($ 194.74M)
Volume:
714.84K
Avg Vol (2M):
279.74K
Also Trade In:
Volume:
714.84K
At Loss
Avg Vol (2M):
279.74K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for AVITA Medical Inc ( ASX:AVH ) from 1993 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. AVITA Medical stock (ASX:AVH) PE ratio as of Apr 19 2024 is 0. More Details

AVITA Medical Inc (ASX:AVH) PE Ratio (TTM) Chart

To

AVITA Medical Inc (ASX:AVH) PE Ratio (TTM) Historical Data

Total 1253
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
AVITA Medical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-19 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss
2024-04-01 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss
2024-03-11 At Loss 2024-01-08 At Loss
2024-03-08 At Loss 2024-01-05 At Loss
2024-03-07 At Loss 2024-01-04 At Loss
2024-03-06 At Loss 2024-01-03 At Loss
2024-03-05 At Loss 2024-01-02 At Loss
2024-03-04 At Loss 2024-01-01 At Loss
2024-03-01 At Loss 2023-12-29 At Loss
2024-02-29 At Loss 2023-12-28 At Loss
2024-02-28 At Loss 2023-12-27 At Loss
2024-02-27 At Loss 2023-12-22 At Loss
2024-02-26 At Loss 2023-12-21 At Loss
2024-02-23 At Loss 2023-12-20 At Loss
2024-02-22 At Loss 2023-12-19 At Loss
2024-02-21 At Loss 2023-12-18 At Loss
2024-02-20 At Loss 2023-12-15 At Loss

AVITA Medical Inc (ASX:AVH) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

AVITA Medical Inc logo
AVITA Medical Inc
NAICS : 339112 SIC : 5047
ISIN : AU000000AVH4

Share Class Description:

ASX:AVH: ADR
Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.